New York, NY July 2019 – Americord Registry announced today the launch of its newest stem cell banking product, Placental Tissue 2.0TM. Americord was one of the first family cord blood banks to store placental tissue and now offers this exciting product, which stores live amniotic membrane (AM), a first for the industry. [Read more…]
Productivity software enables tracking, sharing and collaborating around stem cell research to accelerate scientific discoveries and breakthroughs.
Madison, WI, June 3, 2019 — Cellara, LLC, a software-as-a-service company, announced the commercial release of CultureTrax software V2.0. It is the first productivity software designed to meet the unique needs of stem cell scientists.
Stem cells are a core technology for basic biological and medical research as well as the foundation of rapidly emerging cell-based therapies and disease models for drug development. Discoveries are built on stem cell scientists’ ability to communicate quickly and accurately with one another and reproduce their own work or the work of others. Studies indicate more than 50% of published pre-clinical biology research cannot be easily reproduced (Freedman, et al, 2015).
Outdated methods for documenting experimental details and sharing protocols using static documents and paper lab notebooks are a major source of the problem. Although many labs are adopting electronic lab notebooks, these have not solved the complex cell line tracking and reproducibility challenges unique to stem cell research.
“Our vision is to accelerate scientific discoveries and breakthrough therapies by providing advanced cell culture software,” says CEO Scott Fulton. “CultureTrax software enables you to quickly and easily plan and fully document your cell culture and analytical work. The software also provides a repository for detailed, current protocols and recipes, structured to drive accurate execution in the lab and rapid, comprehensive recording of results.”
Professor Rebekah Gundry of Medical College of Wisconsin has been using CultureTrax software in her lab for two years, and states, “CultureTrax provides immediate, paperless access to protocols, recipes and the experimental plan which minimizes human error and saves us time.”
CultureTrax is a secure web-based application, so you can access your work from anywhere through a browser on your PC or tablet. CultureTrax enables you to easily share both your experimental workload, your protocols and your detailed results with colleagues. This improves the ability of scientists to replicate work and enhance efficiency and progress in the field of stem cell research. For more information, visit www.culturetrax.com.
Cellara is a software-as-a-service company that has developed CultureTrax, a powerful stem cell productivity platform capable of managing the complex needs of stem cell research. It is a Wisconsin-based company headquartered in Madison, a world-class center of the most advanced cell culture science, life science tools industry and information technology. CultureTrax creates a common digital language to empower cell culture scientists to realize the full potential of their research and collaborate more effectively.
Do you have questions about Cellara or its CultureTrax software V2.0? Ask them in the comments below.
On June 24, 2019, Krystal Biotech (NASDAQ:KRYS) became the latest regenerative medicine company to announce that it has received an RMAT designation granted from the FDA for its gene therapy product, KB103. The FDA’s decision was based on positive results from the company’s Phase 2 placebo-controlled clinical trial of KB103 and an update on the results from its Phase 1 study. These studies are named GEM-1 and GEM-2.
The same day, the company announced it had initiated an underwritten public offering of $100.0 million of its common stock. Among other activities, Krystal Biotech intends to use these proceeds to advance KB103 into and through a Phase 3 clinical trial.
Krystsal Biotech’s RMAT Designation
RMAT stands for “Regenerative Medicine Advanced Therapy” designation. Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.
The RMAT designation is well-matched to Krystal Biotech’s product development focus, because it is a gene therapy company focused on commercializing treatments for patients suffering from dermatological diseases.
KB103 is currently being studied for its wound closure capacity in patients with severe generalized recessive dystrophic epidermolysis bullosa (“RDEB”).
As stated by the company:
“KB103’s RMAT designation follows our recent announcement of the Priority Medicines, or PRIME designation received from the EMA, and we look forward to collaborating closely with the EMA and initiating a clinical trial in the EU in the upcoming months. The RMAT pathway is analogous to the Breakthrough Therapy designation designed for traditional drug candidates and medical devices and was specifically created by the U.S. Congress in 2016 to get important new cell therapy and gene therapy products to the patient earlier.
Just like the Breakthrough designation, it allows companies developing regenerative medicine therapies to interact with the FDA more frequently in the clinical testing process, and RMAT-designated products may be eligible for priority review and accelerated approval.”
Headquartered in Pittsburgh, PA, Krystal Biotech is planning a pivotal Phase 3 trial for KB103 planned to start before 2020.
To learn more about Krystal Biotech, view this company presentation by Suma Krishnan, Founder and Chief Operating Officer (COO).
Seeking a searchable, sortable Excel database of RMATdesignations you can use on-the-go? Access one here.
Global Cord Blood Corporation (NYSE: CO) announced June 4, 2019, that its board of directors received a non-binding proposal letter from Cordlife Group Limited for the two companies to combine by way of a statutory merger. Under the terms of the nonbinding proposal, Cordlife will issue its ordinary shares at SGD0.5 per ordinary share, and in exchange, will receive all of the outstanding ordinary shares of Global Cord Blood Corporation (GCBC) at US$7.50 per share. [Read more…]
Collaboration commercializes biological tools to advance the companies’ shared goal of accelerating the field of Regenerative Medicine.
FREDERICK, Md., May 29, 2019 — RoosterBio Inc. and Tissue Regeneration Therapeutics Inc.(TRT) today announced a strategic collaboration to advance their shared goal of accelerating the development of the Regenerative Medicine field. This collaboration will productize TRT’s core technology around human umbilical cord-derived mesenchymal stem/stromal cells (hUC-MSCs) to the entire Regenerative Medicine marketplace. This powerful set of biological tools will be made commercially available via integration into RoosterBio’s unique product formats for rapid incorporation into tomorrow’s Regenerative Medicine products. [Read more…]